ChromaDex Corporation operates as a nutraceutical company. The company offers research and quality control products and services to dietary supplements, food, beverages, cosmetic, and pharmaceutical industries; Nicotinamide riboside (NIAGEN), a novel form of vitamin B3 for enhancing nicotinamide adenine dinucleotide(NAD) level used for healthy aging; Pterostilbene (pTeroPure), a polyphenol and antioxidant used in health related fields; and Immulina, a spirulina extract and compound, which is used for improving human immune function, as well as developing Pterostilbene and caffeine co-crystal ingredients, and anthocyanins ingredients. It also provides reference standards, materials, and kits to conduct quality control of raw materials and consumer products; and fine chemicals and phytochemicals for research and new product development applications. In addition, the company offers a range of consulting services, including regulatory support, product development, risk management, and litigation support. Further, it assists customers in creating processes for manufacturing natural products using green chemistry, as well as developing phytochemical libraries. The company markets and sells its products directly in the United States and Canada; and through international distributors. ChromaDex Corporation has a strategic partnership for healthy aging research with the Jiangxi Provincial Government, the People’s Republic of China. ChromaDex Corporation is based in Irvine, California.

  • New Preclinical Study Finds Niagen® Prevents Light-Induced Retinal Damage in Mice
    on September 9, 2020 at 10:33 am

    ChromaDex Corp. (NASDAQ:CDXC) today announced new preclinical research published in Investigative Ophthalmology & Visual Science finding Niagen® (patented nicotinamide riboside, or NR) prevented light-induced retinal damage in mice. This research paves the way for future preclinical and clinical studies exploring the relationship between NAD+ levels and preservation of long-term ocular health. The study, conducted through the ChromaDex External Research Program (CERP), was led by Jeffrey H. Boatright, PhD, FARVO, Professor of Ophthalmology and principal investigator at Emory University and the Atlanta VA Center for Visual and Neurocognitive Rehabilitation.

  • LD Micro: 360 Companies--Set to Present this Week.
    on September 1, 2020 at 8:34 pm

    LOS ANGELES, CA / ACCESSWIRE / August 31, 2020 / LD Micro today announced the final list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online.

  • ChromaDex to Present at the LD 500 Virtual Investor Conference
    on August 26, 2020 at 10:32 am

    ChromaDex Corp. (NASDAQ:CDXC) today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Kevin Farr, will be presenting at the LD 500 investor conference. The LD 500 will take place on September 1st through the 4th.

  • New Pilot Study Indicates Niagen® May Reduce Inflammatory Cytokines in Stage D Heart Failure Patients
    on August 18, 2020 at 10:32 am

    ChromaDex Corp. (NASDAQ:CDXC) today announced the 11th published human trial on its patented NAD-boosting nutrient Niagen®, further highlighting its potential to support cardiovascular health in humans. A NIH funded study by Cardiology Division and Mitochondria & Metabolism Center at the University of Washington, published in The Journal of Clinical Investigation, found that Niagen supplementation reduced signs of inflammation, specifically inflammatory cytokines in vivo, in a small group of end-stage heart failure patients. A second arm of the study, conducted ex vivo, found improved mitochondrial respiration and reduced inflammatory factor expressions in peripheral blood mononuclear cells (PBMCs) isolated from human subjects and treated with nicotinamide riboside.

  • ChromaDex (CDXC) Reports Q2 Loss, Tops Revenue Estimates
    on August 6, 2020 at 11:10 pm

    ChromaDex (CDXC) delivered earnings and revenue surprises of 45.45% and 12.71%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

  • ChromaDex Corporation Reports Second Quarter 2020 Financial Results
    on August 6, 2020 at 8:01 pm

    ChromaDex Corp. (NASDAQ:CDXC) today reported second quarter 2020 financial results.

  • LD Micro - Announces Preliminary List of Presenters for the LD-500
    on August 5, 2020 at 1:00 pm

    LOS ANGELES, CA / ACCESSWIRE / August 5, 2020 / LD Micro today announced the initial list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online.

  • Will ChromaDex (CDXC) Report Negative Earnings Next Week? What You Should Know
    on July 30, 2020 at 4:33 pm

    ChromaDex (CDXC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • ChromaDex to Report Second Quarter 2020 Financial Results on Thursday, August 6, 2020
    on July 28, 2020 at 10:32 am

    ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Thurs., August 6, 2020 at 4:30 p.m. ET to discuss its financial results for the second quarter ended Jun. 30, 2020. The financial results will be reported in a press release after the close of regular stock market trading hours on the same day as the conference call.

  • New Preclinical Study Finds Niagen® Corrects Social Deficits in Mouse Model of Autism
    on July 16, 2020 at 10:33 am

    ChromaDex Corp. (NASDAQ:CDXC) today announced the results of a new preclinical study published in Nature Scientific Reports investigating the role of Niagen® (patented nicotinamide riboside) in addressing social deficits in Autism Spectrum Disorder (ASD). This new study joins a growing body of preclinical data demonstrating that boosting NAD+ (nicotinamide adenine dinucleotide) levels may have a positive effect on cognitive health. The study was the first to evaluate Niagen® in an Autism model.

ChromaDex Director of Scientific Affairs, Mona Rosene, M.S, RD, #exercises and #meditates in the morning before getting ready for a busy day. What do you do to practice #selfcare?

#mitochondrialdisease is the second most commonly diagnosed serious genetic disease, affecting 1 in 5000 people. It is often inherited or linked to mitochondrial dysfunction--the loss of mitochondrial efficiency, function, and energy production.

At ChromaDex, we value good ideas. Our Quality Control Senior Specialist Richard Swift shares his tip on how to stay creative at work. How do you come up with new #ideas when you're stuck creatively?

New preclinical study finds #Niagen prevents light-induced retinal damage in mice #eyehealth

A special thank you to all the essential workers for your continued hard work and dedication during these unprecedented times. #LaborDay2020

Load More...


What's Your Role?*



Company Description*



ChromaDex Corporation

10005 Muirlands Boulevard
Suite G
Irvine, CA 92618

+1 (949) 419-0288

September 2020

©2020 ALIGNMT LLC | Alignment Strategy | Mergers & Acquisitions | Investor Relations


We're not around right now. But you can send us an email and we'll get back to you, asap.


Log in with your credentials


Forgot your details?

Create Account